Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CELC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Gedatolisib FDA approved Jul 2026 · Revtorpyk |
Breast Cancer | Phase 3 · NCT05501886 | Active not recruiting |
| Doxorubicin | HER2-negative Breast Cancer | Phase 2 · NCT03412643 | Unknown |
| Samotolisib (LY3023414) | Endometrial Cancer | Phase 2 · NCT03675893 | Recruiting |
| Metformin | Endometrial Cancer | Phase 2 · NCT03675893 | Recruiting |
| Weekly Paclitaxel | HER2-negative Breast Cancer | Phase 2 · NCT03412643 | Unknown |
Also used in these trials (approved or third-party drugs, not CELC's own candidates): Alpelisib, Palbociclib, Fulvestrant, Letrozole, Capmatinib, Cyclophosphamide, Darolutamide, Neratinib, Abemaciclib, Pertuzumab, Talazoparib, Trastuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CELC holds $642.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $60.8M/quarter from operations, an estimated runway of 31.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Based on our current business plan, we believe that our current cash, cash equivalents and short-term investments, will provide sufficient cash to finance our operations through 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CELC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP Former 10% owner |
Insider | 4,372,852 | 8.90% | 2026-07-14 |
| Brian F. Sullivan Chief Executive Officer, Director · +1.50M options |
Insider | 3,200,983 | 6.52% | 2026-08-14 |
| Blackrock Inc. | Institution (13F) | 3,177,631 | 6.47% | 2026-09-30 |
| Perceptive Advisors LLC | Institution (13G, 5%+) | 3,160,200 | 6.43% | 2025-12-31 |
| RTW Investments, LP | Institution (13G, 5%+) | 3,039,621 | 6.19% | 2026-03-31 |
| Deerfield Management Company, L.P | Institution (13F) | 2,397,664 | 4.88% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 2,056,176 | 4.19% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 1,941,490 | 3.95% | 2026-09-30 |
| Point72 Asset Management, L.P. | Institution (13F) | 1,764,914 | 3.59% | 2026-09-30 |
| NEA Management Company, LLC | Institution (13F) | 1,710,561 | 3.48% | 2026-09-30 |
| Bank of America Corporation | Institution (13F) | 1,709,364 | 3.48% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 1,532,977 | 3.12% | 2026-09-30 |
Share count 49,126,314 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-07 filed 2026-10-09 |
Furcht Leo |
Option exercise (M) | 250 | $7.60 | 12,780 |
| 2026-10-07 filed 2026-10-09 |
Furcht Leo |
Option exercise (M) | 250 | – | – |
| 2026-10-01 filed 2026-10-05 |
GRYSKA DAVID W |
Award (A) | 893 | – | 893 |
| 2026-08-14 filed 2026-08-18 |
Hahne Vicky |
Award (A) | 16,000 | – | 37,808 |
| 2026-08-14 filed 2026-08-18 |
Sullivan Brian F. |
Award (A) | 80,000 | – | 1,450,199 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-07-17 | REVTORPYK™ (gedatolisib) | NDA | +0.1% | +0.1% | — |
| 2026-05-01 | — | sNDA | +6.3% | +3.5% | +7.7% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →